New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 18, 2023 - The FDA approved revisions to the Imbruvica (ibrutinib) label.
Download PDF
Return to publications
